News | News By Subject | News by Disease News By Date | Search News

Endometriosis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AbbVie (ABBV)'s Elagolix Successful in Second Phase III Study     2/10/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Evotec AG (EVTG.F) and Bayer AG (BAYZF) Enter Into $765 Million Multi-Target Alliance to Fight Endometriosis     10/1/2012
Neurocrine Biosciences, Inc. (NBIX) Phase 2 Endometriosis Drug, Elagolix Meets Goals     5/25/2010
FDA May Lift Hold On Repros Therapeutics Inc. (RPRX)'s Proellex     4/30/2010
Neurocrine Biosciences, Inc. (NBIX)'s Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis     7/29/2009
Repros Therapeutics Inc. (RPRX) Announces that Initial Findings for Proellex(R) Show No Tumorigenic Response in a Two-year Carcinogenicity Study in Rats     7/21/2008
Repros Therapeutics Inc. (RPRX) Says Uterus Drug Significantly Reduces Pain in Trial     7/11/2008
AEterna Zentaris (AEZS) Regains Exclusive Worldwide (ex-Japan) Rights from Solvay for Cetrorelix in Endometriosis Indication     5/8/2007
Repros Therapeutics Inc. (RPRX)'s Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids     4/3/2007
AEterna Zentaris (AEZS) Announces Cetrorelix Development With Solvay Chemicals Inc. Continues With Endometriosis As A Primary Indication     3/16/2005
Columbia Laboratories, Inc. (CBRX) Release: Kronos Longevity Research Institute -KLRI- Changes Protocol For HRT Study     8/16/2004
Spectrum Pharmaceuticals (SPPI) Licenses A Fourth-Generation Phase 2 LHRH Antagonist From Zentaris GmbH (AELA)     8/12/2004

News from Around the Web

Press Releases
Repros Therapeutics (RPRX) Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex In The Treatment Of Endometriosis     12/20/2016
MDNA Life Sciences And University of Oxford To Collaborate To Develop A Mitochondrial Biomarker Blood-Based Diagnostic For Endometriosis     11/1/2016
Repros Therapeutics (RPRX) Provides Phase II Results Showing Positive Outcomes For Oral Proellex In Women With Moderate To Severe Endometriosis     9/8/2016
Enteris Biopharma Initiates Clinical Program For Tobrate (Oral Tobramycin Tablet) In Uncomplicated Urinary Tract Infection     7/13/2016
Neurocrine Biosciences (NBIX) Reports First Quarter 2016 Results     5/6/2016
AbbVie (ABBV) Initiates Enrollment In Phase 3 Clinical Program For Elagolix In Patients With Uterine Fibroids     1/28/2016
ObsEva And Kissei Pharmaceutical Co., Ltd. Announce Global Agreement To Develop And Commercialize KLH-2109 For The Treatment Of Endometriosis     11/20/2015
AbbVie (ABBV), Neurocrine Biosciences, Inc. (NBIX) Drug Successful in Late Stage Endometriosis Trial     1/8/2015
Repros Therapeutics Inc. (RPRX) Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex® In The Treatment Of Uterine Fibroids And Endometriosis     3/18/2014
Repros Therapeutics Inc. (RPRX) Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex® In The Treatment Of Uterine Fibroids And Endometriosis     3/17/2014
AmorChem l.p., Universite Laval And CHU De Quebec Collaborate On The Development Of A Treatment For Endometriosis And Estrogen-Dependent Cancers     12/19/2013
FDA Reclassifies Proellex® Clinical Hold Status: Repros Therapeutics Inc. (RPRX) to Proceed With Phase 2 Study of Low Dose Oral Proellex® in the Treatment of Endometriosis     10/8/2012
Repros Therapeutics Inc. (RPRX) Release: FDA Provides Recommendations for Phase 2 Protocol for Low Dose Oral Proellex(R) in the Treatment of Endometriosis     8/28/2012
FDA Requests Teleconference to Discuss Repros Therapeutics Inc. (RPRX) Phase 2 Protocol for Proellex® in the Treatment of Endometriosis Last Week of August     7/31/2012
Repros Therapeutics Inc. (RPRX) Commences Dosing Third Cohort in Low Dose Proellex(R) Study     3/16/2011